NCT06557668

Brief Summary

This study aims to evaluate the survival and treatment outcomes among colorectal cancer patients undergoing anti-cancer treatment, both with and without an immunomodulator.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
2mo left

Started Aug 2024

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Aug 2024Jul 2026

First Submitted

Initial submission to the registry

August 8, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 16, 2024

Completed
4 days until next milestone

Study Start

First participant enrolled

August 20, 2024

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2026

Last Updated

January 29, 2026

Status Verified

January 1, 2026

Enrollment Period

1.9 years

First QC Date

August 8, 2024

Last Update Submit

January 27, 2026

Conditions

Colorectal Cancer

Keywords

Colorectal CancerAstragalus PolysaccharidesSurvival

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    From the initial treatment until April 2024

Secondary Outcomes (2)

  • Progress free survival

    From the initial treatment until April 2024

  • Tumor response

    From the initial treatment until April 2024

Study Arms (2)

Cancer treatment with immunomodulator

CRC patients had previously received cancer therapies along with immunomodulator

Cancer treatment without immunomodulator

CRC patients had previously received cancer therapies without immunomodulator

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Colorectal Cancer

You may qualify if:

  • Aged 20 years and older.
  • Patients who have been given a diagnosis of colorectal cancer.
  • Patients had previously initiated anti-cancer therapies between January 1, 2020, and Apr 30, 2024.

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Chung-Shan Medical University Hospital

Taichung, Taiwan

NOT YET RECRUITING

Taichung Veterans General Hospital

Taichung, Taiwan

RECRUITING

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Central Study Contacts

Chou-Chen Chen, M.D.

CONTACT

ccchen24615237@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Attending Physician

Study Record Dates

First Submitted

August 8, 2024

First Posted

August 16, 2024

Study Start

August 20, 2024

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 1, 2026

Last Updated

January 29, 2026

Record last verified: 2026-01

Locations

TW(2)